Skip to main content
. 2015 Jun 17;6(23):19542–19551. doi: 10.18632/oncotarget.4295

Figure 3. The C228T mutation causes TERT expression and telomerase activity.

Figure 3

A. Luciferase reporter assays for transcriptional activity of the TERT promoter. Patient#3, #12, #27 represented all the 60 bladder cancer samples. B. TERT mRNA levels in fractionated cells were detected by real-time PCR analysis. C. Telomerase activities in fractionated cells were detected by TRAP assays. D, E. TERT mRNA levels and telomerase activities were analyzed in BCSCs(T228C) and NBBCs(C228T). Patient#1 and #3 represented all the 60 bladder cancer samples. F. The correlation between the C228T mutation of TERT promoter and the TERT expression in BCSCs was analyzed from 60 bladder cancer patients (p = 0.012; r = 0.75, Pearson's correlation). G. Each subpopulation cells were harvested for ChIP assays with anti-ETS1 antibody, followed by PCR for TERT promoter. Data represent three different experiments. **p < 0.01.